The present invention relates to a process for producing a pore-containing granulate, comprising the following steps: a) producing a foamed mass using sand, hydraulic binder, foaming agent and water, b) pouring the foamed mass into a filling mould, c) partially curing the mass over a first period of time at ambient pressure to form a green block having a first target strength, and d) demoulding the green block, the process comprising the further steps e) splitting the green block into at least two sub-blocks, l) further curing the sub-blocks over a second period of time at ambient pressure until a second target strength is reached and g) breaking the sub-blocks to form pore-containing granulate with a desired particle size distribution. Furthermore, the present invention relates to a process for the production of a pore-containing artificial stone which contains the granulate as an additive.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

Single crystals of a new noncentrosymmetric polar oxysulfide SrZn.sub.2S.sub.2O (s.g. Pmn2.sub.1) grown in a eutectic KF-KCl flux with unusual wurtzite-like slabs consisting of close-packed corrugated double layers of ZnS.sub.3O tetrahedra vertically separated from each other by Sr atoms and methods of making same.

Single crystals of a new noncentrosymmetric polar oxysulfide SrZn.sub.2S.sub.2O (s.g. Pmn2.sub.1) grown in a eutectic KF-KCl flux with unusual wurtzite-like slabs consisting of close-packed corrugated double layers of ZnS.sub.3O tetrahedra vertically separated from each other by Sr atoms and methods of making same.

A strand pelletizer for pelletizing a strand of material comprises at least one cutting edge and an opposite cutting edge. The opposite cutting edge is arranged on a base body which is displaceable relative to a support body. The base body is independently displaceable in a linear manner relative to the support body and pivotable about at least one pivot axis. The strand pelletizer enables simple and precise adjustment of the opposite cutting edge and an associated cutting gap.

A strand pelletizer for pelletizing a strand of material comprises at least one cutting edge and an opposite cutting edge. The opposite cutting edge is arranged on a base body which is displaceable relative to a support body. The base body is independently displaceable in a linear manner relative to the support body and pivotable about at least one pivot axis. The strand pelletizer enables simple and precise adjustment of the opposite cutting edge and an associated cutting gap.

A continuous method of producing granules comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid or SNAC. The method comprises: (i) providing a powder comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, (ii) dry granulating the powder by using a roller compactor, (iii) continuously during dry granulation removing material accumulating on roller rims and leading the material towards the outlet. The roller compactor comprises a pair of pressing rollers 212 comprising a first 212a and a second pressing roller 212b, and wherein the first pressing roller 212a comprises roller rims 213. The roller compactor may further comprise a granulator 216, a sieve 218, and an exit chute 203 mounted below the sieve 218. The roller compactor further comprises roller rim strippers 250 for removing material accumulating on the roller rims 213. The roller compactor can further comprise an agitator adapted for agitating product tending to accumulate or build-up below the sieve insert 218.

A continuous method of producing granules comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid or SNAC. The method comprises: (i) providing a powder comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, (ii) dry granulating the powder by using a roller compactor, (iii) continuously during dry granulation removing material accumulating on roller rims and leading the material towards the outlet. The roller compactor comprises a pair of pressing rollers 212 comprising a first 212a and a second pressing roller 212b, and wherein the first pressing roller 212a comprises roller rims 213. The roller compactor may further comprise a granulator 216, a sieve 218, and an exit chute 203 mounted below the sieve 218. The roller compactor further comprises roller rim strippers 250 for removing material accumulating on the roller rims 213. The roller compactor can further comprise an agitator adapted for agitating product tending to accumulate or build-up below the sieve insert 218.

A non-spray-drying, dry-granulation process for making a ceramic particulate mixture including from 4 wt % to 9 wt % water. At least 90 wt % of the particles have a particle size of from 80 μm to 600 μm. The process includes the steps of: (a) forming a precursor material; (b) subjecting the precursor material to a compaction step to form a compacted precursor material; (c) subjecting the compacted precursor material to a crushing step to form a crushed precursor material; and (d) subjecting the crushed precursor material to at least two air classification steps. One air classification step removes at least a portion of the particles having a particle size of greater than 600 μm from the crushed precursor material, and the other air classification step removes at least a portion of the particles having a particle size of less than 80 μm from the crushed precursor material.